Target intelligence / Profile preview

Trace amine-associated receptor 5 (TAAR5)

Target
TAAR5
Molecular classification
G protein-coupled receptor, Receptor, Olfactory receptor (noncanonical)
01

Overview

Trace amine-associated receptor 5 is a member of the trace amine-associated receptor (TAAR) family, one of the class A (rhodopsin-like) G protein-coupled receptors[1][3][7]. TAAR5 is encoded by the *TAAR5* gene and is primarily expressed in the olfactory epithelium of vertebrates, functioning as an olfactory receptor for volatile tertiary amines such as trimethylamine and N,N-dimethylethylamine[7]. It is also expressed in specific brain regions, including the limbic system and cerebellum, where it has been shown to regulate emotional behaviors, postural stability, muscle force, and motor coordination[5][7]. TAAR5 knockout models display altered neurogenesis, dopamine neuron population, and changes in behavioral and sensorimotor profiles. Human genetic variants in TAAR5 influence olfactory perception, particularly sensitivity to fishy odors[7]. Although most TAARs remain orphans, deorphanization efforts have identified several synthetic antagonists and inverse agonists for TAAR5, highlighting its potential as a druggable CNS target for neuropsychiatric, neurodegenerative, and olfactory-perceptual disorders[2][3][8].

Other names
TAAR5Trace amine receptor 5hTAAR5mTAAR5 (species specific)
02

Mechanism of action

Agonists activate TAAR5, primarily modulating olfactory and possibly central nervous system functions. Inverse agonists reduce TAAR5 basal activity. Antagonists inhibit activation by endogenous and exogenous amines, potentially affecting olfactory and CNS signaling.

03

Biological functions

Olfactory signal transduction (detection of volatile amines)Regulation of emotional behaviorRegulation of motor control and postural stabilityModulation of limbic and cerebellar circuitryInfluences neurogenesis and dopamine neuron population
04

Disease associations

Neuropsychiatric disorder (implicated or potential)Neurodegenerative disease (potential/experimental evidence)Motor/vestibular disorders (experimental evidence)Other (olfactory perception-related conditions)
05

Safety considerations

Limited data; potential for CNS effects due to expression in limbic and motor regionsPotential off-target activity due to homology with other aminergic GPCRs
06

Interacting drugs

Trimethylamine (full agonist)

5 more in the full profile.

Beyond the preview

Go deeper on Trace amine-associated receptor 5 (TAAR5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trace amine-associated receptor 5 (TAAR5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call